Optune Pax concomitant with gemcitabine and nab-paclitaxel is the first treatment to be FDA approved in nearly 30 years for locally advanced pancreatic...
Lonza announced the addition of Redberry SAS to its family, strengthening its position as a global leader in quality control solutions for th...
Product Sales Excluding Veklury Increased 4% Year-Over-Year to $28.0 billion for Full Year 2025 Biktarvy Sales Increased 7% Year-Over-Year to $1...
FUJIFILM Biotechnologies expanded manufacturing and process development presence in the North East of England to support vital biomanufacturing innovativ...
MerryLife Biomedical Inc., a clinical-stage biotechnology company focused on neurodegenerative diseases, announced positive Phase 1 results for TML-6, it...
eyonis® LCS aims to redefine lung cancer screening by supporting diagnosis at early, curable stages, while reducing false positives to avoid unne...
Peijia Medical Limited announced that it has formally submitted the European Union Medical Device Regulation (EU MDR) CE Mark registration application fo...
BioArctic AB's (publ) (NASDAQ: BIOA B (Stockholm: BIOA B) partner Eisai announced that the Biologics License Application (BLA) for the treatme...
Rare Patient Voice’s 200,000+ registered patients and caregivers expand Konovo’s ability to deliver connected insights across a broad range o...
Life sciences innovator and leader in precision-engineered synthetic cell mimic technology expands its UK/EU operations to accelerate cell and gene thera...
Initiative will create one of the world's largest multimodal cancer datasets and an integrated suite of AI models and tools to fuel p...
Q4 2025: Net sales of $540 million (+4% at actual rates, +1% at constant exchange rates (CER)); diluted EPS of $0.49 and adjusted diluted EPS of $0.6...
As regulators worldwide intensify scrutiny of per- and polyfluoroalkyl substances (PFAS), laboratories are being pushed into a new era of sensitivity, sp...
Company expects to receive a negative opinion following oral explanation feedback and intends to request re‑examination upon review of formal adoptio...
© 2026 Biopharma Boardroom. All Rights Reserved.
